- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03946150
PaO2/FiO2*PEEP (P/FP) Ratio and Mortality in Acute Respiratory Distress Syndrome.
PaO2/FiO2*PEEP (P/FP) Ratio and Mortality in Acute Respiratory Distress Syndrome
The PaO2/FiO2 (P/F) ratio is same for all the Positive End Expiratory Pressure (PEEP) ≥ to 5. This P/F ratio misleads the severity of disease without the knowledge of set PEEP. The Oxygenation status is actually worse when the patient is using high PEEP.
P/F Ratio doesn't include PEEP in the calculation.The P/F ratio doesn't show the severity of the disease appropriate for the set PEEP.
PaO2/(FiO2 X PEEP) P/FP Ratio is a new Formula which addresses this gap to appropriately calculate the severity of the disease by including PEEP in the formula.
This formula is used to predict mortality for different severities of ARDS.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Main aim of this study is to analyse whether this formula can early diagnose the severity of the disease appropriate for the set PEEP, so the Rescue measure can be started early which can eventually decreases the mortality.
Increasing the PEEP Value with the same Fio2 gives a different PaO2 and SpO2. The oxygenation improves substantially by increasing only the PEEP. So including the PEEP in calculating the severity of Oxygenation is better than the current practice.
The current Definition of ARDS for Oxygenation is P/F Ratio of 300 to 200 is Mild, 200 to 100 is Moderate and less than 100 is Severe ARDS with PEEP ≥ 5.
The New P/FP Ratio of 300 to 200 is mild, 200 to 100 is moderate and less than 100 is severe Adult Respiratory Distress Syndrome (ARDS) for all the different levels of PEEP values.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore
- National Universty Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Intubated patients for
- Adult Respiratory Distress Syndrome
- Stroke
- Seizures
- Post neurosurgery
- Endoscopy Procedure
- Post Cardiac Collapse
Exclusion Criteria
Non intubated patients on
- Room Air
- Nasal Cannula
- Face mask
- Venturi Mask
- Non Rebreathing mask
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
P/FP Ratio
P/FP Ratio is calculated in ARDS Patients retrospectively and analyse whether this new formula with PEEP can appropriately diagnose the Severity of Oxygenation with different levels of PEEP.
|
PaO2/Fio2 X PEEP
|
P/F ratio
P/F ratio is the current Berlin definition of ARDS in Calculating the severity of Oxygenation.
|
PaO2/Fio2 X PEEP
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To predict mortality of ARDS patients using P/F and P/FP Ratio
Time Frame: Baseline ABG done at (approximately 4 hour after intubation) to ABG done approximately 1 hour before Rescue therapy like Neuro Muscular blockage, Proning, ExtraCorporeal Membrane Oxygenator, and High Frequency Oscillatory Ventilation.
|
To predict mortality of different seventies of ARDS between P/F and P/FP Ratio.
Day 1 ABG is taken and calulate the P/F and P/FP Ratio and analyze whether the new formula can predict the mortality on Day 1 after intubation.
|
Baseline ABG done at (approximately 4 hour after intubation) to ABG done approximately 1 hour before Rescue therapy like Neuro Muscular blockage, Proning, ExtraCorporeal Membrane Oxygenator, and High Frequency Oscillatory Ventilation.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Sunitha PalaniDurai, National University Health System, Singapore
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NUHSSingapore
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adult Respiratory Distress Syndrome
-
Wolfson Medical CenterUnknown
-
Centre Hospitalier Universitaire de NiceCompletedRespiratory Distress Syndrome,AdultFrance
-
Abbott NutritionTerminatedAcute Lung Injury | Respiratory Distress Syndrome,AdultRussian Federation
-
GlaxoSmithKlineTerminatedLung Injury, Acute and Respiratory Distress Syndrome, AdultUnited Kingdom
-
Amazon UniversitySanta Casa de Misericórdia do ParáCompletedSepsis | HELLP Syndrome | Postpartum Period | Respiratory Distress Syndrome,Adult
-
Michael A. MatthayThe University of Texas Health Science Center, Houston; United States Department... and other collaboratorsCompletedRespiratory Distress Syndrome, AdultUnited States
-
Faron Pharmaceuticals LtdSeventh Framework ProgrammeTerminatedRespiratory Distress Syndrome, AdultSpain, United Kingdom, France, Italy, Finland, Czechia, Belgium, Germany
-
Karolinska University HospitalKarolinska InstitutetUnknownAcute Respiratory Distress Syndrome, AdultSweden
-
Michael A. MatthayMassachusetts General Hospital; National Heart, Lung, and Blood Institute (NHLBI) and other collaboratorsCompletedRespiratory Distress Syndrome, AdultUnited States
-
Chang Gung Memorial HospitalUnknownRespiratory Distress Syndrome, AdultTaiwan
Clinical Trials on P/FP Ratio
-
National University Health System, SingaporeActive, not recruiting
-
FHI 360Ministry of Health, UgandaCompletedCommunity-based Delivery of Integrated Family Planning/HIV Testing and Counseling Services in UgandaHIV Testing and CounselingUganda
-
Immune Targeting Systems LtdCompleted
-
Foresee Pharmaceuticals Co., Ltd.Completed
-
CSL BehringCompletedHemophilia BUnited States, Japan, Israel, Austria, Bulgaria, France, Germany, Italy, Russian Federation, Spain
-
University of California, San FranciscoPopulation Services InternationalCompleted
-
Fervent PharmaceuticalsICON plcCompletedVasomotor Symptoms | MenopauseUnited States
-
Five Prime Therapeutics, Inc.ParexelCompleted
-
CSL BehringCompletedHemophilia BGermany, Australia, Italy, Israel, Czech Republic, Spain, France, Canada, Austria, Russian Federation
-
Foresee Pharmaceuticals Co., Ltd.Recruiting